Dr. Malcolm Kendrick discusses recent concerns in the medical community regarding the potential for bias in clinical research on statin therapy. He reviews the various reasons statin trials may be unreliable, including selective publication of results and strategic shifting of trial endpoints during ongoing studies. Despite the apparent evidence-based support of statin therapy and measures taken in the 1990s and early 2000s to mitigate bias, Kendrick urges doctors to proceed with caution when recommending the drugs. Echoing another review from 2015, Kendrick claims “a complete reassessment [of their efficacy and safety] is mandatory.”